Soluble Fas and the −670 Polymorphism of Fas in Lupus Nephritis

Table 4

Characteristics of the individual studies of the −670 (A/G) Fas polymorphism in SLE and sFAS adapted from [33, 34].

Studies	Years	Country	sFas levels g/mL; SLE/controls	Numbers; SLE/controls	A alleles (%); SLE/controls	Association; value
Hatef et al. [35]	2013	Iran	409.38/168; = 0.03	32/46	ND	ND
Moudi et al. [36]	2013	Iran	ND	106/149	58/49	0.03
Pradhan [37]	2012	India	4771.5/1131.4; = ND	70/70	58/42	0.001
Molin et al. [38]	2012	Germany	ND	46/96	37/11.5	0.001
Man et al. [39]	2012	China	ND	552/718	61.1/58.1	NS
Araste et al. [40]	2010	Iran	158.1/48.7; = 0.001	249/212	51.6/49.5	NS
Sahebari et al. [25]	2010	Iran	372.2/190.3; = 0.001	114/50	ND	ND
Mahfoudh et al. [41]	2007	Tunisia	0/3,200	0/170	0/57	ND
Xu et al. [42]	2004	China	ND	103/110	NS	NS
Kanemitsu et al. [43]	2002	Japan	ND	109/140		0.004
Lee et al. [44]	2001	Korea	ND	87/86	NS	NS
Al-Maini et al. [45]	2000	United Arab Emirates	600/260; = 0.0001	39/22	ND	ND
Huang et al. [19]	1997	Australia	ND	79/86	NS	NS
Jodo et al. [21]	1997	Japan	870/220; = 0.001	77/40	ND	ND
Present study	2014	Mexico	1094.41/630.44; = 0.001	67/54	48/63	0.03

sFas: soluble Fas, SLE: systemic lupus erythematosus, ND: undetermined, NS: not significant.